Antibodies News and Research

RSS

Researchers highlight potential advantages of mucosal vaccine

Anyone who has undergone a nasal swab or saliva test for COVID-19 knows that the virus is most easily detected in the nose and mouth.

30 Nov 2020

Female reproductive hormones may be protective against COVID-19

In an article recently published in Trends in Endocrinology & Metabolism, Graziano Pinna from the University of Illinois in Chicago outlines some of the evidence suggesting that female reproductive hormones may play a role in the sex bias that has been observed in coronavirus disease 2019 (COVID-19).

29 Nov 2020

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

A new study reports a very promising anti-SARS-CoV-2 monoclonal antibody, HB27, that appears to have two distinct mechanisms of action inhibiting the virus-host cell interaction and subsequent infection.

27 Nov 2020

N439K mutation of SARS-CoV-2 may be more infectious and antibody resistant than Wuhan strain

Researchers from the Harbin Institute of Technology, China, modeled the complexes formed between the RBD and the human ACE2 and monoclonal antibodies.

27 Nov 2020

COVID-19 studies have neglected to focus on mucosal immunity, researchers argue

Researchers suggest that COVID-19 studies should focus on how mucous membranes in the mouth and nose develop immunity to the SARS-CoV-2 virus.

27 Nov 2020

Siemens Healthineers SARS-CoV-2 IgG antibody test demonstrates ability to detect neutralizing antibodies

Siemens Healthineers has announced its SARS-CoV-2 IgG Antibody Test has proven to measure neutralizing antibodies and has achieved CE Mark. The test is an enhanced version of the assay which became available globally this summer.

From Siemens Healthineers 27 Nov 2020

HIV alters SARS-CoV-2 immune response without affecting COVID-19 symptoms or outcomes

In a preprint paper published on the medRxiv server, a team of researchers from various institutions in South Africa, the UK, and Europe discuss how they determined the impact of HIV on the COVID-19 immune response in KwaZulu-Natal, South Africa, which is an area with very high HIV prevalence.

26 Nov 2020

SARS-CoV-2 immunity can sustain for at least eight months, study finds

A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.

26 Nov 2020

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer is poised for clinical testing to begin in December.

25 Nov 2020

New analytical method to detect the patulin toxin in foods by using antibodies

The University of Valencia and Spanish National Research Council have patented a method to detect the patulin toxin in foods by using antibodies.

25 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

A recent study based at a hospital in Buenos Aires, Argentina, found that convalescent plasma therapy for patients with severe COVID-19, and COVID-19-related pneumonia, was largely ineffective.

25 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Is COVID-19 severity mediated by higher antibody response?

A new study indicates that patients with more severe COVID-19 have a stronger antibody response.

25 Nov 2020

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

A study conducted by researchers based in Italy suggests that SARS-CoV-2 induces durable and strong immunity in patients who had moderate to severe COVID-19.

25 Nov 2020

Study shows how high frequency sound waves could revolutionize ultrasound-driven chemistry

Researchers have revealed how high-frequency sound waves can be used to build new materials, make smart nanoparticles and even deliver drugs to the lungs for painless, needle-free vaccinations.

25 Nov 2020

Austrian study shows robust antibody response to SARS-CoV-2 for over 6 months

In the face of discouraging news about the resurgence of COVID-19, some reports offer hope of protection in the face of a robust and persistent immune response. In an encouraging report, an Austrian preprint appearing on the medRxiv server in November 2020 suggests a high level of durable immunity to SARS-CoV-2 over at least six months.

24 Nov 2020

Protection of upper respiratory tract will require vaccines that mimic natural infection by SARS-CoV-2

Recently, a team of researchers studied the transmission modes of SARS-CoV-2 and the protection against re-infection in ferret models in work published on the preprint server, bioRxiv.

24 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Antibodies News and Research

Researchers highlight potential advantages of mucosal vaccine

Female reproductive hormones may be protective against COVID-19

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

N439K mutation of SARS-CoV-2 may be more infectious and antibody resistant than Wuhan strain

COVID-19 studies have neglected to focus on mucosal immunity, researchers argue

Siemens Healthineers SARS-CoV-2 IgG antibody test demonstrates ability to detect neutralizing antibodies

HIV alters SARS-CoV-2 immune response without affecting COVID-19 symptoms or outcomes

SARS-CoV-2 immunity can sustain for at least eight months, study finds

Early interferon therapy may mitigate COVID-19 severity

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

New analytical method to detect the patulin toxin in foods by using antibodies

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Is COVID-19 severity mediated by higher antibody response?

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

Study shows how high frequency sound waves could revolutionize ultrasound-driven chemistry

Austrian study shows robust antibody response to SARS-CoV-2 for over 6 months

Protection of upper respiratory tract will require vaccines that mimic natural infection by SARS-CoV-2

Mild COVID-19 disease may trigger long-term immunity

Antibodies eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News